Drug Discovery World

OCTOBER 21, 2022

Under an exclusive agreement, Jazz Pharmaceuticals will acquire development and commercialisation rights to Zymeworks’ zanidatamab across all indications and all territories except for those Asia/Pacific territories previously licensed by Zymeworks. billion, plus royalties on net sales.

Antibody 52

Antibody Licensing Licensing Sales 52

pharmaphorum

JUNE 23, 2021

GlaxoSmithKline’s pitch to shareholders kicked off this afternoon with an optimistic view of its late-stage pipeline – including some big sales predictions for products like its respiratory syncytial virus (RSV) vaccine and new blood cancer drug Blenrep. billion takeover of Tesaro in 2019. £1 mRNA ambitions. mRNA ambitions.

Sales 100

Sales Vaccination Vaccine Drugs 100

Delveinsight

JANUARY 12, 2021

Medivir, IGM Biosciences enters into an exclusive licensing agreement for Birinapant. Medivir AB has entered into an exclusive licensing agreement with IGM Biosciences to receive global, exclusive development rights for Birinapant. AvantGen Enters into a Licensing Agreement for its Anti-SARS-CoV-2 Antibodies with IGM Biosciences.

Licensing 52

Licensing Licensing Antibody Gene Therapy 52

pharmaphorum

JULY 8, 2022

Swedish rare disease specialist Sobi is paying $55 million upfront to license rights to ADC Therapeutics’ lymphoma therapy Zynlonta – approved in the US last year – in Europe and other international markets. The post Sobi bolsters blood division via $435m ADC licensing deal appeared first on.

Licensing 52

Licensing Licensing Sales Marketing 52

pharmaphorum

OCTOBER 18, 2022

Gilead Sciences has made yet another rush into the oncology category, licensing a bispecific antibody from MacroGenics in development as a treatment for CD123-positive blood cancers, including acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Along with the signing fee, there is another $1.7 It brought in $4.7

Antibody 52

Antibody Sales Clinical Trials Clinical Trials 52

Pharmaceutical Technology

MAY 8, 2023

Reddy’s Laboratories have partnered for the development and commercialisation of the anti-PD-1 monoclonal antibody, toripalimab, in 21 countries. The company may also choose to expand the scope to license toripalimab in New Zealand, Australia, and in nine other countries. Junshi Biosciences may get an aggregate of up to $728.3m

Development 130

Development Marketing Licensing Licensing 130

pharmaphorum

AUGUST 10, 2021

Seagen is a specialist in antibody-drug conjugates, but has looked to Chinese biotech RemeGen for a HER2-targeting candidate that could challenge rival drugs from AstraZeneca/Daiichi Sankyo and Roche. While the licensing deal with Seagen tops up its finances, the scale well below the $6.9 Sales last year grew by a third to $1.7

Licensing 52

Licensing Licensing Antibody Sales 52

Drug Discovery World

JANUARY 5, 2023

Synaffix and Hummingbird Bioscience have entered into a licensing agreement that it is hoped will enable Hummingbird Bio to develop an antibody drug conjugate (ADC) programme using Synaffix technology. .

Licensing 52

Licensing Licensing Antibody Sales 52

Pharmaceutical Technology

DECEMBER 19, 2022

With the latest development, Sanofi will licence a NK cell engager programme that acts on B7H3 from the antibody-based NK cell engager therapeutics (ANKET) platform of Innate. Initially, the companies signed a research collaboration and licensing agreement in 2016 to develop and assess up to two bispecific NK cell engagers.

Development 264

Development Engineer Clinical Trials Clinical Trials 264

pharmaphorum

NOVEMBER 10, 2021

The drug was the first in the oral CGRP inhibitor class to get an prevention indication approved by the FDA in May, and that has helped accelerate its rollout, bringing in $336 million in US sales for Biohaven so far this year. The post Pfizer strikes $1.2bn licensing deal for Biohaven migraine drug appeared first on.

Licensing 52

Licensing Licensing Drugs Sales 52

pharmaphorum

JUNE 16, 2022

MorphoSys seemingly inexorable shift into an oncology pure-play has continued with an out-licensing deal for two programmes in the kidney disease and immunology categories to China’s HIBio. The move comes after MorphoSys announced in March that it would be cutting swathes of its early-stage pipeline in the wake of its $1.7

Licensing 104

Licensing Licensing Antibody Sales 104

Pharmaceutical Technology

NOVEMBER 18, 2022

Regeneron Pharmaceuticals has entered a collaboration and licensing agreement with CytomX Therapeutics for developing conditionally-activated bispecific cancer therapies. Under the deal, the companies will work together on the discovery activities for identifying and validating the conditionally active bispecific antibodies.

Development 130

Development Antibody Licensing Licensing 130

The Pharma Data

APRIL 12, 2023

Program uses Denali’s Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagement Biogen Inc. Nasdaq: DNLI) today announced that Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV): Amyloid beta program (ATV:Aβ).

Antibody 40

Antibody Development Engineer Licensing 40

Pharmaceutical Technology

MARCH 23, 2023

Seagen specialises in developing antibody-drug conjugates (ADCs) which will complement Pfizer’s oncology portfolio. This figure derives from net product sales in addition to revenues gained from royalties and licensing agreements. Seagen generated almost $2 billion in revenue in 2022, an increase approaching 25% from 2021.

Licensing 147

Licensing Licensing Sales Trials 147

Roots Analysis

FEBRUARY 26, 2024

Given the robust pipeline of biologics, which include monoclonal antibodies, vaccines and other protein-based therapeutic products, subcutaneous medications are being investigated for various clinical candidates across different phases of development. You can also download the SAMPLE REPORT on subcutaneous medications by Roots Analysis.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Drugs Contract Manufacturing 52

pharmaphorum

JANUARY 13, 2022

Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson’s disease, licensing a bispecific antibody from South Korea’s ABL Bio in a deal that could be worth more than $1 billion. Despite the interest, there have already been some failures in the alpha-synuclein category.

Antibody 98

Antibody Drugs Protein Licensing 98

pharmaphorum

NOVEMBER 18, 2022

Using CytomX’s Probody and Regeneron’s Veloci-Bi platforms, the collaboration and licensing agreement aims to enable the development of investigational next-generation bispecific immunotherapies. Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc.

Antibody 105

Antibody Sales Development Licensing 105

pharmaphorum

DECEMBER 2, 2021

Novartis has licensed a potential drug for Parkinson’s from Belgium’s UCB that it thinks could be the first oral, disease-modifying drug for the disease – if it can avoid the fate of earlier drugs in the class. billion if the drug reaches the market and hits sales objectives.

Antibody 111

Antibody Licensing Licensing Gene Therapy 111

Pharmaceutical Technology

SEPTEMBER 28, 2022

Seagen also will make potential development, regulatory and commercial milestone payments of up to nearly $650m, as well as royalty payments on the sales of the product in the future. According to the deal, Lava will receive an upfront payment of $50m from Seagen for the exclusive worldwide licence of LAVA-1223.

Licensing 130

Licensing Licensing Development Sales 130

Pharmaceutical Technology

AUGUST 16, 2022

Q32 will also receive tiered royalty payments on net sales. antibody, ADX-914 re-regulates adaptive immune function by hindering IL-7 and TSLP-facilitated signalling. On Horizon exercising the option, Q32 could be entitled to further receive up to another $645m in closing and milestone payments. A fully human anti-IL-7R?

Development 130

Development Clinical Trials Clinical Trials FDA Approval 130

Drug Discovery World

MARCH 27, 2023

Macomics and Ono Pharmaceutical have entered a worldwide drug discovery collaboration agreement to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in cancer. Ono will have an exclusive option to license global rights to the candidates for further development and commercialisation.

Drugs 52

Drugs Antibody Genome Genomics 52

The Pharma Data

APRIL 9, 2021

Biogen enters into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a proposed biosimilar referencing ACTEMRA ® (tocilizumab). In 2020 global sales of ACTEMRA ® were 2.8 Biogen Inc. Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. billion CHF.

Licensing 52

Licensing Licensing Manufacturing Production 52

pharmaphorum

JUNE 18, 2021

Japan’s Eisai has hit the jackpot with its first ever antibody-drug conjugate (ADC) drug candidate, attracting a licensing deal from Bristol-Myers Squibb that could top out at more than $3.1 antibody with cell-killing drug eribulin – sold on its own by Eisai as Halaven.

Antibody 98

Antibody Licensing Licensing Sales 98

pharmaphorum

JANUARY 7, 2021

The partnership covers up to five oncology targets identified by OBT using its discovery platform, and the UK firm will try to develop antibodies against them. Kite and Gilead will then develop and commercialise therapies based on these targets or antibodies.

Research 110

Research Antibody Sales Development 110

pharmaphorum

APRIL 10, 2022

Seagen claims Enhertu (trastuzumab deruxtecan) – an antibody-drug conjugate (ADC) targeting HER2 – infringes a patient it holds (No. 10,808,039) covering ADCs that include auristatin compounds coupled to an antibody via a linker molecule. billion licensing deal for the drug in 2019. That could be a sizeable sum.

Sales 52

Sales Antibody FDA Approval Drugs 52

pharmaphorum

JUNE 4, 2021

Bayer has agreed to buy Noria Therapeutics and its subsidiary PSMA Therapeutics, adding to its pipeline of radionuclide drugs for cancer as sales of its lead product in the category – Xofigo – continue to decline. . The technology behind the drug was licensed from Weill Cornell Medicine and Johns Hopkins University in the US.

Antibody 81

Antibody Licensing Licensing Sales 81

pharmaphorum

DECEMBER 14, 2020

Daiichi Sankyo and AstraZeneca could be just weeks away from an EU approval for their antibody-drug conjugate (ADC) for breast cancer – Enhertu – which is tipped to become a multibillion-dollar blockbuster. If all the pieces fall into place it reckons peak sales could reach $4.5 billion upfronting a deal that could be worth up to $6.9

Sales 105

Sales Antibody Drugs Medicine 105

Pharmaceutical Technology

JANUARY 19, 2023

However, it is possible to target CD33 in the clinic, as evidenced by the FDA approval of Pfizer’s anti-CD33 antibody-drug conjugate Mylotarg (gemtuzumab ozogamicin) in 2000. NiCord’s biologics license application is currently being investigated by the FDA with a review date set by May 2023.

Marketing 130

Marketing Gene Editing Production Sales 130

The Pharma Data

JANUARY 12, 2021

million additional doses of the casirivimab and imdevimab antibody cocktail, bringing total potential U.S. Under the new agreement, the government will purchase all finished doses of the casirivimab and imdevimab antibody cocktail delivered by June 30, 2021 , up to 1.25 TARRYTOWN, N.Y. , 12, 2021 /PRNewswire/ — . million doses.

Antibody 52

Antibody Production Manufacturing Clinical Trials 52

pharmaphorum

OCTOBER 4, 2021

Enhertu is already approved as a third-line therapy for HER2-positive breast cancer, but moving the drug up the treatment pathway could make it an option for a larger group of patients and accelerate sales growth. billion upfront to license rights to Enhertu in a deal that could be worth up to $6.9 AZ paid a hefty $1.4

Sales 78

Sales Antibody Drugs Licensing 78

pharmaphorum

FEBRUARY 2, 2022

billion settlement as well as royalties on sales of one of its top HIV products. Along with the one-off settlement, Gilead has agreed to pay ViiV a 3% royalty rate on Biktarvy sales and any other bictegravir-containing product in the US until 5 October 2027, when ViiV’s US patent on dolutegravir expires. Revenue fall.

Sales 72

Sales Production Drugs Licensing 72

pharmaphorum

DECEMBER 23, 2021

Novartis is hoping that with Leqvio it will see rapid take-up, in contrast to the antibody drugs which rolled out slowly amid pushback from payers that wasn’t overcome by substantial price cuts. Novartis added inclisiran to its pipeline after buying The Medicines Company – which had licensed the drug from Alnylam – for $9.7

Drugs 105

Drugs Sales Antibody FDA Approval 105

Pharmaceutical Technology

FEBRUARY 14, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin 1, which are now well established in the industry.

Antibody 130

Antibody Hormones DNA Licensing 130

pharmaphorum

SEPTEMBER 23, 2022

AstraZeneca has taken the decision not to move a PCSK9-targeting antisense drug licensed from Ionis into a phase 3 programme, removing a competitor to Novartis’ rival therapy Leqvio. billion in sales by 2027, ahead of Repatha at $2.2 billion in sales by 2027, ahead of Repatha at $2.2

Drugs 59

Drugs Licensing Licensing Sales 59

pharmaphorum

FEBRUARY 21, 2022

It’s a key moment for the two companies, as expansion into HER2-low breast cancer has been held up as a key requirement for Enhertu (trastuzumab deruxtecan) if it is to achieve its multibillion-dollar sales expectations. billion upfront to license rights to Enhertu in a deal that could be worth up to $6.9 AZ paid a hefty $1.4

Trials 132

Trials Sales Hormones Drugs 132

pharmaphorum

DECEMBER 22, 2020

The latest deals include a license agreement with San Diego-based Ligand Therapeutics , which has a subsidiary producing technology for neurological disorders. million on the table if certain development, regulatory and sales goals are achieved. This deal involves an upfront payment of $7 million but there is up to $154.5

Licensing 52

Licensing Licensing Genetics Sales 52

The Pharma Data

DECEMBER 29, 2020

First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. NASDAQ: REGN) today announced encouraging initial data from an ongoing Phase 1/2/3 clinical trial of the Regeneron antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen. futility analysis).

Antibody 52

Antibody Trials Production Clinical Trials 52